Welcome to the Novartis Presentation at the 42nd JP Morgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JP Morgan. It's my great pleasure to welcome Vas Narasimhan, the CEO of Novartis, today. Before I hand over to Vas, I'll just remind everyone we're going to take Q&A after Vas' presentation in this room. Vas, welcome to the conference.
Thank you. Thank you, Richard, and, great to be here today. Always wonderful to be at JP Morgan to start the year and give all of you an update on where Novartis is and, and where we're going. What I'd like to do is give you an overview of a little bit of our journey over the last few years, and then talk about the future, and I think pretty exciting prospects for us as a company. Now, when you look at our overall profile, in summary, we think we've come to a place where we really present investors an attractive story, a focused strategy with four core plat- five core platforms, four k- core TAs, strong capital allocation approach.
We highlighted at our recent R&D Day a commitment to grow 5% through 2027, as well as 40%+ margins, really putting us at the top end of the peer set. A robust pipeline with 10+ phase III readouts in 2023, and we'll go through that, as well as 83 projects in the pipeline. We've slimmed down the pipeline, but we think the pipeline now is really filled with attractive assets. And then a leader in ESG. We're a leader in many of the key indices, and we take it seriously to continue to do the right things to contribute to society. Now, when you look at Novartis over the last decade, we've really now completed what was a substantial transformation of the company.
In 2014, we were a diversified healthcare group, spanning a large number of sectors, and progressively, with the exit of consumer health, the exit of Alcon, the exit of Sandoz, each is now independent companies with attractive spins to shareholders that were tax neutral. We end up as a focused medicines company today entering 2024. And when you look at that transformation and how it's impacted our financial profile, our margins have substantially improved to now 37%, marching up to that 40%. As well as you just look at the free cash flow generation of our business, now at $11 billion through three quarters, and we expect a strong quarter four as well. 32.4% of sales now getting into free cash flow.
So it really shows that we are doing the right things that not only improve the strategy of the company, but also the financial return profile of the company. And when you look at our financial performance over the last five years, in spite of LOEs, in spite of challenges, we've grown sales at 7% on our innovative medicines business. We've grown our core operating income at 14% on that IM business, and like, as I've mentioned, that core margin up 790 basis points. So showing that we can deliver that steady financial performance consistently over time now, since 2018. Now, as we look ahead, we remain very committed to our focus strategy, which we outlined really two years ago, along therapeutic areas, platforms, four priority geographies with a big goal to raise our presence in the U.S..
Of course, delivering returns and being a leader on foundations and continuing to be strong on operational excellence. We continue a big commitment to culture. We continue to believe culture drives performance in the long run, and I think we're seeing that now start to come through in the operating performance of Novartis. We also stay consistent with our approach to capital allocation, with a balanced approach, investing in the business. We fully invest in R&D, as well as our manufacturing and other capital needs, and continue to do value-creating bolt-ons, about CHF 33 billion now over the last five years, while consistently growing our dividend in Swiss francs, independent of the various spins that we've made. We've committed to continue to grow that dividend and a consistent approach to share buybacks.
We have a $15 billion share buyback now ongoing, following the past $15 billion share buyback we recently completed, and we've already talked about the exits that we've done in a shareholder-friendly way. We've also been active on the BD&L and M&A front, and I wanted to highlight some of the deals we announced this morning. Over the course of the last year, we did about 15 strategic deals totaling around $600 billion. A few we announced this morning, Argo Biopharma, a partnership with a siRNA company, where we've now brought in three different assets that we have either options or will be licensing and developing within cardiovascular disease. We recently announced the partnership with CKD, with an HDAC6 inhibitor and atrial fibrillation.
This morning, we announced the acquisition of Calypso Biotech with an anti-IL-15 in immunology, so very excited about bringing that into our immunology portfolio. We also announced our partnership with Isomorphic Labs on the AI front. That's a Google DeepMind company working on developing using AI to prosecute drug development targets. So a broad range of deals, and we'll continue to really look at those deals in that sub-$2 billion, sub-$1 billion dollar space to continue to build out the portfolio. Now, turning to our growth profile, we outlined at a recent R&D day our belief that we can grow at 5%. That's an upgrade from the 4% previous CAGR from 2022 to 2027, 40% plus margin.
That's driven that by primarily the growth drivers and the pipeline outpacing the LOEs that we have with Entresto, Tasigna, and Promacta. I want to get into a little bit more detail as well on this individual peak sales for some of those assets. Then when you look at the longer term, we believe we have the pipeline and portfolio to grow 5% to 2027 and then mid-single digit beyond. Broad range of de-risked end market brands that you can see listed here. A number of pipeline assets. As I mentioned, I'm going to walk through the 10+ readouts.
Just this morning, we announced Scemblix, one in the frontline setting, hitting all primary and secondary endpoints against standard of care, a choice of TKI, Gleevec or second generation TKI, showing again the kind of assets that we're able to bring forward out of our portfolio.... So turning into our in-market brands, we outlined at the recent investor meeting our peak sales in each one of these in-line assets, upgrading particularly the guidance on Entresto, now to $7 billion of peak sales, maintaining our Cosentyx at $7 billion, upgrading Kisqali with a belief that medicine can now get to $4 billion+. Kisqali solely in the metastatic setting, not in the adjuvant setting. We'll get to that on the next slide, $4 billion.
And then Pluvicto now as our radioligand therapy platform, multi-billion dollar potential, and of course, Leqvio, our siRNA in cardiovascular disease, also with a multi-billion dollar peak sales potential. I think what's really exciting about our portfolio is that many of these assets have now a next leg coming up with the recent data readouts. When you look at Cosentyx, that's $7 billion, but we continue to have, I think, some pretty exciting recent launches. With Cosentyx, we launched Cosentyx IV, which is off to a very strong start in the United States. We also had the approval of Cosentyx in hidradenitis suppurativa, which gives us another exciting indication to move forward in dermatology. With Kisqali, we had the readout, positive readout of the adjuvant indication, and I'll talk more about that.
Pluvicto, with multiple opportunities to move into earlier lines of therapy to add another multi-billion dollars on top of the multi-billions we've already guided to. And of course, Leqvio, with its outcome studies, as well as moving Leqvio into the frontline setting as well, gives an opportunity to drive stronger growth. So taken together, when you look at our strategy from a therapeutic area standpoint, we've defined specific diseases that we want to win in, and these are diseases that we manage centrally now as a company aligned in R&D through commercial, and we, of course, constantly are thinking about which diseases we need to add or exit. We have anchor brands in each one of those therapeutic areas, which give us strong commercial, medical affairs, and development presence in those TAs.
And then we have multiple assets in those TAs that we can bring forward and continue to leverage that global commercial R&D and medical affairs infrastructure. So now I want to turn to what I think was a banner year for Novartis in R&D. Over the course of the year, we had 10+ phase III readouts or data presentations on assets with significant potential. These are all assets now that are either recently approved or in the process of getting filed over the course of this year, and we think can give more confidence, not only in that 5% out to 2027, but our belief will grow mid-single digits into the 2030s. I won't get into some of the earlier, mid-stage pipeline and emerging phase III that would read out in the 2025, 2026 time frame.
I think it's a great opportunity to review for all of you kind of these core assets. So starting with Kisqali at ASCO, we showed the phase III NATALEE study, which demonstrated consistent benefit, and then we updated that at San Antonio Breast, showing that breast cancer, showing that we had consistent improvements in iDFS in both stage two and stage three with a positive trend in OS. I can say now today, we have completed the filing of Kisqali in the U.S., following the filing in EMA with a priority review voucher. We would expect to be able to bring this forward in the course of 2024. Again, a very strong profile overall, no new safety signals, a compelling profile that allows this medicine, we believe, to be used not only in high risk, like the currently approved therapy, but also in intermediate risk.
I would say that Kisqali is doing extremely well in the metastatic setting. Right now, we are leading an NBRx share in the US with a steady progress in TRx as well. We also see multiple markets outside the United States. Kisqali is getting to the point in the metastatic setting to being the market leader. On Pluvicto, we read out the PSMAfore study, which showed robust efficacy, great safety and efficacy profile overall. We nearly doubled or doubled median RPFS. Very consistent benefit, whether it's in patient benefit with time to worsening the FACT-P or the BPI-SF. Overall, I think a really nice trial to support the broadened use of Pluvicto.
We will be working now to get to the next information fraction cutoff of 75% events in the early part of this year, which we hope will then allow us to move forward with the filing with FDA. As a reminder, this is a study with really high rates of crossover, over 80%. Part of that is because the medicine is doing so well right now in its current line, post-chemo, in the U.S. and in Europe. We got it to roughly $1 billion in sales in 2023, and we expect that march in its current indication to continue forward. On Friday, we announced that Pluvicto new manufacturing site in Indianapolis is approved, giving us yet another large-scale manufacturing site. It's our largest in the world, and that allows now for radioligand therapy.
We are fully supply unconstrained, both for Lutathera, Pluvicto, and our pipeline. Now moving to Fabhalta, this is iptacopan, our factor B inhibitor, which showed outstanding data in the Apply and Appoint studies for efficacy and safety in PNH. We received approval in December for Fabhalta in the U.S. with a very attractive label, which allows us to be both frontline, add-on, or a salvage therapy for these patients, and now are in the active approach of launching this medicine in the U.S. with plans then ultimately bring it around the world. Very excited about this data, and I think it demonstrates that we can raise the standard of care for diseases that...
like PNH, with an oral therapy twice a day with an attractive profile. iptacopan then demonstrated later on, last year, positive data in the C3G trial, a rare kidney disease, but again, demonstrating that it had a clinically meaningful and statistically significant impact on proteinuria reduction in this patient population. Again, a very good safety profile, consistent with what we saw in the PNH setting. We'll be presenting this data later this year, but this will be the next leg for iptacopan to continue to expand across a broad range of indications. We have ongoing studies with iptacopan in other indications, such as, membranous glomerulonephritis, as well as atypical hemolytic uremic syndrome, among others. But importantly, with iptacopan, we also read out positively in IgAN, which gave us a 3+ readout on this medicine in a single year.
Now, we have two assets with positive readouts in IgAN over the course of 2023, both iptacopan and atrasentan read out positive. We're now in the process of filing both of these medicines in the U.S. and then eventually around the world. This allows us to really build out a next leg in our cardiorenal portfolio, having multiple assets with iptacopan, with atrasentan to give patients with kidney diseases the next better therapies that they, of course, all need to avoid transplant and some of the other adverse consequences of renal disease. Then in the mid-stage pipeline, we continue on our phase III study of zigakibart, which is a monoclonal antibody that we're currently evaluating, and that would give us yet another asset within the IgAN portfolio. We also read out positive data on remibrutinib.
This is our BTK inhibitor in the REMIX-1 and REMIX-2 studies in chronic spontaneous urticaria. Here, the data demonstrated, we would argue, near biologic-like efficacy with a very good safety profile, without any signals within a liver disease with liver signals of any concern. This gives us the opportunity to not only move forward with a submission in 2024 with remibrutinib, but also to take remibrutinib now into a further range of immunology indications. While we do have the multiple sclerosis studies ongoing as well, we see the opportunity to expand this medicine in multiple immunology indications, given its strong safety profile as well as high efficacy. So we're very excited to provide updates on those phase III starts as we make them over the course of 2024. Next, turning to our radioligand therapy pipeline.
This one was a little bit under the radar, but something we're quite excited about. Lutathera read out positive in its phase III NETTER-2 study. This is in the frontline setting in combination with high-dose Sandostatin. Gives us the opportunity to take this medicine, which is already a $500 million-plus medicine in later-line therapy of neuroendocrine tumors, and move it into the frontline setting. What's exciting about this, in the US, we already have a broad label, that allows us for the medicine to be used in that frontline setting. We just didn't have the data yet. So this is a medicine, that met its primary endpoints. We'll be presenting this data, at one of the ASCO satellite meetings in the first quarter of this year, so at ASCO GU.
We believe this gives us an opportunity now to have, given our long history of Sandostatin LAR in the frontline setting, a next wave medicine that redefines the standard of care for these patients and gives us a next leg of growth within radioligand therapies and within that whole treatment of neuroendocrine tumors. This is also a medicine now we're taking forward in small cell lung cancer in combination with PD-1 inhibitors, and we also have ongoing studies in glioblastoma multiforme to give us a kind of next leg next to Pluvicto for, for radioligand therapy. One of the things we did highlight in our R&D day was a very strong portfolio of RLTs behind these two frontline medicines. Let me turn to Scemblix.
So this morning, in this slide we just updated right before my presentation, we announced that, in the ASC4FIRST study, Scemblix hit its primary and secondary endpoints, clinically meaningful and statistically significant improvements in MMR rate versus investigator choice TKIs, Gleevec or second-gen TKIs. Basically, it's favorable safety and tolerability profile. I mean, from our perspective as the company that brought Gleevec to the world in 2001 and redefined the opportunity to treat patients with targeted therapies in cancer, then bringing forward Scemblix to now once again raise the standard of care in the frontline setting with an oral medicine, I think is one of the triumphs of Novartis scientists and Novartis chemistry. So we're very excited about this data.
This will build on our third-line data, ongoing phase IV studies in the second line, both mono and in combination, and now in the frontline setting. We think what makes this medicine special is not only high efficacy, but a very strong safety profile. So this is obviously data we'll be presenting later this year at an upcoming medical congress with a submission plan in 2024, and a significant medicine we think now for Novartis. So taken together, we expect 15 key submissions in our core therapeutic areas by 2027. You can see here the full range. I talked about many of them. One of the ones I didn't talk about, but we're excited about, is ianalumab, which is a CD40 ligand, BAFF receptor, CD40 ligand inhibitor.
So we think pretty exciting medicine as well within our immunology portfolio, among others. I did want to say a word on our next wave platforms that we think can drive our long-term growth, and you see a lot of BD&L activity from Novartis on this front. Radioligand therapies, we've talked about CAR-T and immunology you heard in the last presentation, but we also believe that we have a unique asset with our YTB medicine that has the opportunity to deliver significant clinical outcomes for patients with immunological disease. So we continue to expand out our clinical trials as well, and we think this will become a very significant space. We've already presented our first three patients in treating SLE at a congress last year and demonstrated, I think, very, very compelling results, consistent with what the German investigators have found.
And they, of course, are now at 18 months, two years, showing full remissions in these patients. And lastly, siRNAs, not only in cardiovascular disease, also in neuroscience. We did DTx earlier last year, and then I mentioned Argo Biopharma, giving us, I think, more and more assets within siRNA, ASOs, alongside our partnership with Ionis as well, giving us, I think, a pretty attractive early portfolio to use these medicines in treating neuroscience and cardiovascular disease. So in closing, I just wanted to also highlight our strong commitment within ESG, something we take seriously as a company.
We've really repositioned Novartis as one of the leaders, both in terms of how we create value for society with the work we do, but also ensure whether it's in the environment, ethical standards, or other enablers, we're doing the right things for the world in how our company operates. And just to close with a story that I feel a lot of pride in as a public health physician, leading an incredible company like Novartis, our commitment to malaria spans decades. We took Nobel Prize-winning work from a Chinese scientist and brought the world Coartem. We are now at over 1.2 billion courses of Coartem provided to patients around the globe at no profit to Novartis, including 400 million children. We've created formulations and new programs.
We also have the most of the malaria pipeline in the industry, and then we recently announced we'll be starting a study to be able to treat infants, newborn infants for malaria with our medicines. I think this is the kind of work we want to do alongside the other work to demonstrate we're a company that really drives the health improvements for the planet. So in closing, coming back to where I started, a focused strategy, clear and attractive growth prospects with unique assets that can drive that growth, a robust pipeline demonstrating that we have the R&D engine with 10+ readouts in 2023, and an ESG leader doing the right things for the world. So I look forward to taking your questions, meeting with many of you over the course of the day, and then keeping you updated on Novartis over the course of this year.
Thank you all very much.
Thanks, Vas. We're moving to the Q&A portion, so if you have a question, I think raise your hand. Otherwise, maybe I'll kick off. You know, you highlighted this raising of your growth rate, so maybe you could just talk about the pushes and pulls around that and how confident you are. What could deliver more growth than you expect? What are the risks?
You know, Richard, coming out of 2022, where, as you're aware, we did a pretty significant restructuring of the company, focused down, in 2023, we saw a significant re-rating of how we were performing on our in-line brands, as well as all of these positive, pipeline readouts, which led to the three guidance upgrades we gave over the course of the year. So a lot of ways, that 4%-5% is just mathematical from just that step up that we saw in 2023. And, and I think that's really underpinned by those assets I talked about, those big growth drivers, as well as now having confidence that Kisqali, Pluvicto, iptacopan, Lutathera, now Scemblix, will all come through in that period, alongside some of the deals we did, like the Chinook acquisition.
That gives us that confidence that 5%+ is really within reach, and obviously we'll want to do even better. I think for us, the next part of the story, and we discussed this in London when we were together, is really giving more confidence in that 28-33 period. I think proof like Scemblix today, Scemblix is a drug that is not exposed to IRA. It's an orphan disease. So we have a runway through the 2030s on a market that historically has delivered $3 billion-$5 billion medicine. So I think we need to get a couple of more of those, I think, to give everyone more confidence on that next wave. We have it. We also have to demonstrate it to all of you.
There's a question over there.
Thank you. Angus Liu, Fierce Pharma. So just looking at the summary, BD summary, that slide, it struck me that I think Novartis right now, the only major oncology player that hasn't done any deals in ADCs. So I was just wondering, because I understand you have some ADCs within your pipeline, and it is not your priority technology, but just how did you resist the temptation?
You know, we have a long history within research of ADCs, but we have not been successful, I think, to be clear. But a part of our focus strategy is looking at places where we think we can create long-term sustainable leadership, and we are investing in radioligand therapies. I mean, we believe that the therapeutic index on radioligand therapies, when you find the right target, gives you a pretty wide window to get a therapeutic effect without some of the safety issues. We saw that with Lutathera. We saw that with Pluvicto. I didn't highlight it, but, you know, I think Richard saw it in London. Behind Pluvicto, we have multiple actinium-based compounds, which give us the next wave of assets within the prostate cancer space.
We have three or four other targets, FAPI, Folate, Bombesin, Integrin, all in the clinic. And then when you think about some of the successful ADCs, we now are advancing HER2 and HER3 RLTs into late preclinical, and we hope to get into the clinic with the belief that, as you all know, some of these ADCs have some pretty extreme toxicities. I mean, we saw that in the data at ESMO. I mean, you have category five toxicities, which are deaths. And if you can avoid that with radioligand therapy but still get that high efficacy, and given we have completely unconstrained supply now with all the investments we made, we think that's a better place to focus our capital versus over-indexing on ADCs at the moment.
Maybe we can build there and, on the radioligand therapy and around Pluvicto, you know, what's been the physician response, and how wide adoption can you get, given they are quite technical to give, within the hospital setting?
It's a good point, and especially as we move to the pre-taxane setting, and then our goal ultimately to move into the hormone-sensitive setting with the PSMA addition study. We will need to move from about 300 centers today that can administer Pluvicto, we think, to around 500, and continue to build out capacity within the community, both in urology as well as in nuclear medicine to provide the therapy. So that's a big, big focus. I think that will be a constraint early, but then eventually... What we see is, in general, patients and physicians have the experience of a four-six cycle drug that gives you high efficacy and a nice safety profile, relatively speaking.
I mean, if you look at the PSMA 4 data, cross-trial comparisons with all of the caveats, certainly our data looks pretty good versus ARPIs. And so I think, you know, from a safety standpoint, I think one of the trends in cancer care right now is that patients not only want high efficacy, but they want more tolerable drugs. They want drugs that don't mean a complete sacrifice in terms of how they're living their lives, and I think we can deliver that with Pluvicto.
Got a question over here. Kastberg ?
Yeah. Morten Kastberg, Copenhagen, Denmark. A market leader such as Novartis, can you talk a little bit about what, precision medicine and how you're incorporating that into the pipeline? Because I did not really see that on any of the slides.
Yeah. I think on, on precision medicine, we've taken the approach... We did have large investments. We even had divisions within Novartis that were generating precision medicine, tests. We've largely, divested those, and we take much more of an asset-based approach. So based on a given asset, we will partner typically with precision medicine companies to develop the relevant biomarker tests, et cetera, or try to bring those tests in as we get into translational medicine. We realize some of our peers make very large in-house, internalize, that capability. We believe that doing it more through a network of partnerships makes sense. It's very relevant within the world of, of RLT, not really typical precision medicine, but you need a diagnostic always next to the RLT to be able to identify the, the patients.
While we do have internal capabilities for both PET and gallium-based diagnostics, we take the approach of using a network of partnerships, and I think that's how we'll do things going forward.
Got another question over there.
Thank you for a great presentation. Ebrahim Delpassand from RadioMedix. What is your vision about other types of alpha emitters in radioligand therapy?
Yeah, it's a very good question, and of course, I think, as you heard from the previous presentation, that, you know, RayzeBio being an alpha-emitting company. Now, I think for those of you who aren't spending a lot of time learning about radioligand therapy science, you know, beta emitters and alpha emitters have a very different profiles. I mean, beta emitters have a broader, more diffuse radiation, less concentrated on the target. Alpha emitters are very potent at a short distance and have less potency as you move a little bit further away. The other things we see with beta and alpha emitters, which is the absolute key, is xerostomia. So what knocks out the salivary glands?
And then also with respect to renal and bone marrow, can you find a clear safety profile in which to dose up? So to date, alpha emitters, I think the verdict is still out. We have our own alpha emitters in-house. We've also licensed them in. We acquired some with Endocyte as well. We are developing alpha emitters, both on PSMA as well as other targets, because we think we need to have that. There are other alpha emitters other than actinium, as you surely know as well, which we also evaluate. But, you know, the question for us now is: In which settings would beta emitters make the most sense, and which settings would alpha emitters make the most sense? Can you give alpha emitters after beta emitters? So right now, our actinium PSMA lead program is in a post-Pluvicto setting.
So patients who progress on Pluvicto, a beta emitter, then you move them onto an alpha emitter. So these are all of the scientific questions I think that have to get clarified over the coming years to really know which emitter is gonna be better for which setting, but there's no question you need both in your portfolio to be a leader in RLT.
Maybe just before the next question, maybe logistics as well and half-life. I mean, maybe you want to touch on that and some of the differences that you've found with the, you know, Pluvicto and on the logistics.
So first, I would say this is not for the faint of heart. If you think about all the companies that all of you are following, you know, we live in a world, we typically have six months of inventory or one year of inventory, so that if we have supply disruptions, you just, no issue, you have the inventory on hand. Here, we have no inventory on these medicines. In the case of Lutathera, it's three-four days. In the case of Pluvicto, we have five days, and you're in a very short window to get the medicines to patients. We've now successfully built up through our supply chain the ability to get these medicines to patients, and now we target 1 day before administration. That's our goal, to get the medicine.
But it's been a three-four year journey to build out that supply chain. So to your point, Richard, alpha emitters, beta emitters have different profiles, depending on how they're formulated in terms of time. But I would say, regardless, as a company, you have to be able to navigate between four-max six days between production run release and then getting it to the patient anywhere in the globe.
Hi, Edmonds from AlTi. I had a quick question on your cardiology franchise. Obviously, with Entresto coming off and inclisiran finally starting to really kind of see some traction, could you just talk about where you see Novartis's cardio and kind of capital deployment and how you're thinking about the strategy?
Yeah, first on Entresto, different timelines in different parts of the world. We have the appeal ongoing in the U.S. We continue to guide to a mid-2025 for forecasting purposes, LOE for Entresto in the U.S. In Europe, we have till 2027. In China, it'll be in the 2024-2025 timeframe. In Japan, where the medicine is doing extremely well, we have till 2033, give or take. So obviously, a lot of room, which is why we upgraded Entresto to $7 billion. On Leqvio, slow and steady uptake, but we do see that steady trend now continuing to climb in the U.S., in Europe, but we also see very strong uptake in China, and then we also see now the opportunity in Japan to bring Leqvio forward in a pretty exciting way. So that's next.
And then on the pipeline side of things, Lp(a), of course, pelacarsen, is now on track, continues to be on track for a readout, and that's going to be, I think, the next wave for us within cardiovascular, is to get that Lp(a). And then behind that, the deals that we're doing within siRNA, on the one hand, and we continue to believe getting to once yearly dosing on HMG-CoA reductase, on PCSK9, on, angiotensin II. Those are the deals we just announced this morning. give us an opportunity for our next wave, especially, you know, we'll see how IRA unfolds, but we're certainly on a race to get a next gen Leqvio out there before IRA hits. So that's a, a big, big priority. And then you've seen also some of the activity we have in atrial fibrillation as well.
So a big focus in as well within research on trying to get this next wave of assets forward.
Did you learn anything kind of from Entresto? I mean, obviously, you bought The Medicines Company. I don't think the market developed as fast as you thought. Obviously, you've had to put a lot of work into it. Is that the way you kind of look when you think about the future of cardiology? It is these markets with innovative medicines that you have to develop, and that's really going to be the next drive, is bring the innovation and then create the markets.
Yeah, I think it is a challenge when you think about IRA and cardiovascular disease. There's no question, because these markets take time to develop. It... Entresto took seven years, six-seven years before we hit a strong inflection point. Certainly with Leqvio, we're hoping to get that to happen faster. If you have a nine year pseudo-genericization event on the other end, you're on a tight timeline. Part of the, you know, our strategy, again, flex the siRNAs, ASO-related technologies, and we continue to be hopeful that we can shape both the IRA generally to move from nine to 13, but also specifically within genetically targeted therapies. There's bipartisan legislation out there to try to get the legislation to recognize that siRNAs, ASO should be viewed differently than typical small molecules. That's a huge priority for us as a company.
Maybe on IRA, it was mentioned the, or you mentioned the LOE for Entresto, but it's also up as one of the first drugs on the IRA list.
Yeah.
So, you know, maybe you could tell us how you're seeing that negotiation, if there's anything or what's coming?
I'm not sure I'd characterize it a real negotiation. We've submitted lots of documents, and we continue to submit our case for why we believe Entresto is unique and should, the value should be properly recognized. But that's why we also guide that. Look, you know, the LOE is going to happen somewhere between 2025 and 2027, and also probably in 2026 timeframe, you're going to have a price cut on this medicine in any case. I think some of the interesting dynamics on Entresto, for just understanding the IRA legislation, is this is a medicine where we give significant gross to nets anyway. And so depending on how you interpret the legislation, are we no longer going to give those gross to nets to Part D plans and instead give them to the government, then it's a net neutral proposition.
I, I don't know if the government really has thought through yet how it's going to manage this. I think that's something we'll be watching, and the whole sector has to watch, because in our view, it should not be stacked on top of rebates we are already providing, these PBMs. Rather, it should be in lieu of, in which case, on highly rebated drugs, it could be neutral, right? Depending on the situation.
Makes sense. You mentioned, Oh, we got one question over there.
Angus. I guess we didn't give you an interview, Angus, so we're going to just do it here.
You better be. I think you guys, the team was kind of put on spot during the R&D day when the FDA unveiled that CAR-T investigation. After going through that first database, Kymriah appeared to have the most T-cell lymphoma cases. I know, given the various limitations of the database, I was just wondering how you think that perceived imbalance, a higher rate of T-cell lymphoma, will affect ... the next wave of the T-Charge and,
Yeah.
the next wave of T-cell therapies that the market is.
It's a good question, and I think we have to take it seriously. Just to be clear, though, I think what FDA is specifically looking for is integration events. So are these cancers—so you—in general, in these patients who have DLBCL, FL-related cancers, they do have high rates of recurrence because you are conditioning the bone marrow. And so when you do bone marrow conditioning, you do increase the rates of cancer recurrence, hematological malignancies in these patients. It's sort of a consequence of that. The question is, when you use lentivirus, are you seeing integration events that are pro-cancer? And if you remember, even at the first Kymriah ADCOM many years ago, that was a big question. I can say within our assessments, we don't see integration events within Kymriah. I don't know about the other companies.
I think certainly with YTB, within immunology, we will have to keep watching carefully as we take that into a range of immunological diseases. Do we see those integration events? I think the real question now for CART in immunology is: How early are you gonna be able to go? I mean, these, these results are staggering. When you talk to patients, and you hear the stories of patients who are in the final stages of some of these immunological conditions, and they have complete remissions in three months, just... It's something you just don't see in medicine. So amazing result. Right now, restricted to very late-stage patients in these diseases. The question is: Can we demonstrate the safety to allow us to go earlier? Can we reduce conditioning so that it's less onerous, so you reduce the rate of some of these cancers?
Could you use bispecifics, tri-specifics, other approaches to get similar results? I think that's where the next wave of effort is gonna have to be to really enable more patients ultimately to benefit for these type of therapies.
You talked about the rollout of Leqvio in China. Maybe you could give us an update on how the China business is going and what the growth potential is there. I mean, there's been some problems with obviously the Chinese looking at and doctors not prescribing drugs, but-
Yeah. You know, overall in China, we set out a goal back in 2018 to double the business. We're on track to do that. So approaching a $4 billion business within China, second largest for the company, growing in the high teens. Entresto growing extremely well, Cosentyx, now we have Kisqali approved, so a lot of growth drivers in China. With Leqvio, it's been very interesting to see that within the private market, we're seeing self-pay for this medicine. And it does point to the opportunity you have when you have such a large middle class, that you can have self-pay opportunities with medicines like this. So overall, we're optimistic on China.
I think in order to win in China, you have to be able to have the commercial execution to ramp quickly and then manage well when you do get into the value-based pricing system, that you can manage the decline. So I don't believe that this will be like genericization events in the U.S. I think you can manage the decline in a thoughtful way, but that's a lot of the work that you have to do, I think, in the market.
Excellent. I think we're out of time.
Great.
Thank you very much, Vas.
Thank you all very much.
Good to see you.
Wish you a great conference.